WO2005092340A1 - 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain - Google Patents
1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain Download PDFInfo
- Publication number
- WO2005092340A1 WO2005092340A1 PCT/EP2005/051328 EP2005051328W WO2005092340A1 WO 2005092340 A1 WO2005092340 A1 WO 2005092340A1 EP 2005051328 W EP2005051328 W EP 2005051328W WO 2005092340 A1 WO2005092340 A1 WO 2005092340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- compound
- alkyl
- post
- benzopyran
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 85
- 230000036407 pain Effects 0.000 title claims abstract description 73
- MTYYDFXUUJQQRS-UHFFFAOYSA-N batoprazine Chemical class C=12OC(=O)C=CC2=CC=CC=1N1CCNCC1 MTYYDFXUUJQQRS-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 239000000203 mixture Substances 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 208000004296 neuralgia Diseases 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- AHWHLBJKIFHNIV-UHFFFAOYSA-N 3-amino-8-piperazin-1-ylchromen-2-one Chemical compound C=12OC(=O)C(N)=CC2=CC=CC=1N1CCNCC1 AHWHLBJKIFHNIV-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 206010065390 Inflammatory pain Diseases 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 208000004550 Postoperative Pain Diseases 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 208000008035 Back Pain Diseases 0.000 claims description 5
- 206010058019 Cancer Pain Diseases 0.000 claims description 5
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 206010043269 Tension headache Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000002981 neuropathic effect Effects 0.000 claims description 4
- 230000003040 nociceptive effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001107 psychogenic effect Effects 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010049589 Afterbirth pain Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000018380 Chemical injury Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 206010033892 Paraplegia Diseases 0.000 claims description 3
- 208000000450 Pelvic Pain Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 206010061363 Skeletal injury Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 208000003827 Vulvar Vestibulitis Diseases 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 230000009278 visceral effect Effects 0.000 claims description 3
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 206010028836 Neck pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 230000001270 agonistic effect Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 19
- 230000027455 binding Effects 0.000 abstract description 12
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract description 9
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract description 6
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 32
- 241000700159 Rattus Species 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 229940125904 compound 1 Drugs 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 210000002683 foot Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000000548 hind-foot Anatomy 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000000763 evoking effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 208000004454 Hyperalgesia Diseases 0.000 description 7
- 229920005372 Plexiglas® Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000004926 polymethyl methacrylate Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 208000005298 acute pain Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 5
- -1 hydroxyl - methylene Chemical class 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000005518 mononeuropathy Diseases 0.000 description 5
- OEZOEKHVZJTQBL-UHFFFAOYSA-N n-(6-bromo-8-nitro-2-oxochromen-3-yl)acetamide Chemical compound BrC1=CC([N+]([O-])=O)=C2OC(=O)C(NC(=O)C)=CC2=C1 OEZOEKHVZJTQBL-UHFFFAOYSA-N 0.000 description 5
- WKVKUHYMJHWCAW-UHFFFAOYSA-N n-(8-amino-2-oxochromen-3-yl)acetamide Chemical compound C1=CC(N)=C2OC(=O)C(NC(=O)C)=CC2=C1 WKVKUHYMJHWCAW-UHFFFAOYSA-N 0.000 description 5
- 230000008906 neuronal response Effects 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 4
- YEYPSUQQZNDKDE-UHFFFAOYSA-N 5-bromo-2-hydroxy-3-nitrobenzaldehyde Chemical compound OC1=C(C=O)C=C(Br)C=C1[N+]([O-])=O YEYPSUQQZNDKDE-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- JFLDOKNNEIVQMY-UHFFFAOYSA-N n-(2-oxo-8-piperazin-1-ylchromen-3-yl)acetamide Chemical compound C=12OC(=O)C(NC(=O)C)=CC2=CC=CC=1N1CCNCC1 JFLDOKNNEIVQMY-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 4
- 229960003708 sumatriptan Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 210000001032 spinal nerve Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124433 antimigraine drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 238000002684 laminectomy Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010065347 Premenstrual pain Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010062225 Urinary tract pain Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- ORTYMGHCFWKXHO-UHFFFAOYSA-N diethadione Chemical compound CCC1(CC)COC(=O)NC1=O ORTYMGHCFWKXHO-UHFFFAOYSA-N 0.000 description 1
- 229960003675 diethadione Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000021731 hypoalgesia Diseases 0.000 description 1
- 230000036032 hypoalgesia Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a novel use of known 1 -[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives, broad spectrum 5 -HT receptor binding compounds, having amongst other functional serotonin receptor activities, potent 5 -HT 1A -agonistic as well as 5-HT 1D -antagonistic activity.
- the invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art.
- the invention also relates to the use of a compound of the Invention for the manufacture of a medicament for treating or preventing a disease or condition.
- the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art.
- specific compounds disclosed herein are used for the manufacture of medicaments for pain.
- Acute pain is a normal sensation triggered in the nervous system to alert an individual to possible injury.
- Chronic pain results from persisten t pain signals in the nervous system which continue after the initial damage or injury has disappeared.
- Chronic pain can occur in the absence of any past injury or evidence of body damage, so-called psychogenic pain.
- the invention had the object of providing a medicament for the treatment of pain containing at least one compound with a molecular mechanism of action different from that of all currently marketed analgesics, and thus of therapeutic value in pain conditions not satisfactorily treatable with known analgesics
- 2H-1-benzopyran-2-one (hereafter named 'compound 1'), a broad spectrum 5-HT receptor binding compound, having amongst other functional serotonin receptor activities, potent 5-HT 1A -agonistic, 5-HT 1D -antagonistic activity, as well as 5-HT 7 - agonistic activity (see receptor binding profile, below) , was found to be potently active in experimental animal models of pain.
- the compound is devoid of sedative effects when given in dosages of up to 100 mg/kg p.o. , and was also shown to be highly active as inducers of growth factors. The latter activity is indicative of neuroprotective effects and improvement of brain plasticity required for neuroregeneration , and also indicative of potential therapeutic effects in n europathic pain (see P.
- the pharmacological activities as realized in the compounds of the invention an d their salts represents a novel class of analgesic compounds for the treatment of chronic pain disorders or in treating other conditions where there is hyper - sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain.
- the invention relates to compounds of the general formula (1)
- R t is alkyl(1 -4C), alkoxy(1 -4C), hydroxyl, alkoxy(1 -4C)alkyl(1-4C), pyrrolidinyl, piperidinyl, morpholinyl, halogen, cyano, trifluoromethyl, amino, or mono - or disubstituted amino wherein the substituents are alkyl(1 -4C), or alkyl(1 -4C) carbonyl, m has the value 0, 1 or 2,
- R 2 is alkyl(1 -4C), alkoxy(1 -4C), halogen or trifluoromethyl, n is 0 or 1 , on the understanding that (m + n) is at least 1 , R 3 is hydrogen, alkyl(1 -3C) or alkenyl(2-3C) R 4 is alkyl(1 -4C), and p has the value 0, 1 or 2,
- 5-HT 1D recep tors are located presynaptically on the nerve terminal and have a negative modulatory influence on the release of 5-HT. Therefore, blockade of these receptors enhances the release of 5-HT from its terminals.
- Prodrugs of the compounds mentioned above are in the scope of the present invention.
- Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites.
- Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule. These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry: Principles and Practice, 1994, ISBN 0 -85186-494-5, Ed.: F. D. King, p. 215; J. Stella, "Prodrugs as therapeutics". Expert Opin. Ther. Patents. 14(3). 277- 280, 2004; P.
- Pro-drugs i.e. compounds which when administered to humans by any known route, are metab olised to compounds having formula (1), belong to the invention.
- this relates to compounds with primary or secondary amino or hydroxy groups.
- Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl - methylene derivative, an 0-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enaminone.
- compositions may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
- a suitable acid for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
- the active compounds and their salts can be processed to compositions by means of standard methods, for example pills, tablets, coated tablets, capsules, powders, injection liquids and the like, using auxiliary substances such as liquid and solid carrier materials.
- the invention particularly relates to the compound 3-amino-8-(1-piperazinyl)-2H-1- benzopyran-2-one and the salts thereof, i.e. the compou nd of formula (1 ) wherein (R ⁇ )m is 3-NH 2 , (R 2 )n, R ⁇ and (R 4 ) p are hydrogen, thus having formula (2):
- the compounds of the invention are active at doses in the range of 0.1 — 100 mg/kg after oral administration, and their unique pharmacological profile makes them particularly useful in the treatment of pain.
- pain shall refer to all types of pain.
- the term shall refer to all types of chronic pain including nociceptive, neuropathic, psychogenic pain, and mixed category pain (nociceptive and neuropathic components).
- This in particular includes, but is not limited to, diabetic neuropathy, neurogenic pain, central pain, somatic pain, visceral and cancer pain, inflammatory pain, post-operative pain, chronic low back pain, sciatica, cervical and lumbar pain, tension headaches, cluster headaches, chronic daily headaches, herpes neuralgia and post-herpetic neuralgia, facial and oral neuralgias and myofascial pain syndromes, phantom limb pain, stump pain and paraplegic pain, dental pain, opioid resistant pain, post-surgical pain including cardie surgery and mastectomy, pain of labour and delivery, post-partum pain, post-stroke pain, angina pain, genitourinary tract pain including pelvic pain and cystitis and vulvar vestibulitis and orchialgi
- Sub-types of nociceptive pain are somatic pain and visceral pain.
- Somatic pain includes inflammatory pain, post -operative pain, chronic low back pain, cervical and lumber pain, cluster headaches, dental pain, pain of labour and delivery, postpartum pain, pain resulting from bums or chemical injury or sunburn, and bone injury pain.
- Visceral pain includes cancer pain, post -surgical pain including cardie surgery, angina pain, genito-urinary tract pain including pelvic pain and cystitis and vulvar vestibulitis and orchialgia and pre-menstrual pain syndrome.
- Sub-types of neuropathic pain are diabetic neuropathy, cancer pain, neurogenic pain, central pain, sciatica, herpes neuralgia, post-herpetic neuralgia, facial and oral neuralgias, phantom limb pain, stump pain and paraplegic pain, opioid -resistant pain, post-surgical pain including mastectomy and post -stroke pain.
- Sub-types of psychogenic pain are chronic daily headaches and tension headaches.
- Sub-types of mixed category pain are cancer pain, myofascial syndromes and tension headaches ⁇ e.g. McCaffery M, Pasero C. Pain:Clinical Manual p19 St. Louis: Mosby 1999; Merskek H and Bogduk (eds) Clas sification of chronic pain, 2"" edition, IASP Task Force on Taxonomy, p 209 -214, IASP Press, Seattle 1994; The Merck Manual, Section 14, Chapter 167, Pain, UEdition Merck & Co 1999 ).
- IBS irritable bowel syndrome
- the compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid carrier material.
- the pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsules), ointments (creams or gel) or suppositories.
- Suitable excipie ⁇ ts for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
- auxiliary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention.
- Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sa le for human or veterinary administration.
- the objective of these studies is to evaluate the potential analgesic properties of a test substance in the Bennett and Xie model of peripheral mononeuropathy (see: G.J. Bennett and Y-K. Xie, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man”. Pain. 33, 87-107, 1988).
- n 10 rats/group
- vehicle control reference substance
- 3 dosing groups for test substance.
- 2 days baseline testing, surg ery to induce a peripheral mononeuropathy and monitoring of the development of the neuropathy using behavioural testing on days 10 and 11 post-operatively (PO).
- Chronic drug administration subcutaneous (either by twice daily injection, or continuous infu sion via osmotic mini-pumps), starting on day 12 PO for 14 days and behavioural testing at four time points post -dose for mechanical allodynia.
- Rats are prepared in batches (with members of each treatment group in each batch), and the behavioural tests and dosing is run at fixed intervals after surgery for each batch.
- the behavioural tests (see below) are performed on all rats for a period of 2 days prior to surgery, to establish base -line values.
- a peripheral mononeuropathy is then induced by placing four loosely constrictive ligatures around the right common sciatic nerve under aseptic conditions. The animals are allowed to recover from surgery for a minimum of 4 days before the behavioural testing is recommenced (B. Lynn and S.E. Carpenter, "Primary afferent units from the hairy skin of the rat hind limb ", Brain Research. 238, 29-43, 1982)
- the behavioural testing is resumed on day 10 post-operatively (PO), and is repeated on day 11 to monitor the development of allodynia.
- Drug treatment is carried out from day 12 PO (the time -point corresponding to maximal behavioural changes), or as defined in the study protocol, and a time -course of behavioural tests is carried out. Animals showing any signs of autotomy of the affected digits are terminated. Any animal which does not develop a peripheral mononeuropathy (as determined by the results of the behavioural tests employed in a particular protocol) is not used in the study.
- the withdrawal threshold is defined as being the lowest force of two or more consecutive Von Frey filaments to elicit a reflex withdrawal response (i.e. a brief paw flick).
- Neuropathic pain test (Chung test) in the rat according to Kim and Chung (Pain 1992, 50: 355-363): tight ligature of spinal nerves in rats is associated with hyperalgesia, allodynia and spontaneous pain, and therefore constitutes a model for peripheral neuropathic pain in humans. Antihyp eralgesics reduce these chronic signs of pain hypersensitivity.
- Rats (180-220 g) are anesthetized (sodium pentobarbital 40 mg/kg i.p.) and an incision at the L4-S2 level is performed to expose the left L5 and L6 spinal nerves. A ligature is tied tightly around each nerve. The wound is then sutured.
- the rats receive an i ⁇ tra muscular (i.m.) injection of 50 000 IU Penicilline and are allowed to recover. At least 2 weeks after the surgery, when the chronic state is fully installed, rats are submitted consecuti vely to thermal and tactile stimulation of both the non-lesioned and the lesioned hindpaws.
- the apparatus consists of 6 individual Plexiglas boxes (17 x 11 x 13 cm) placed upon an elevated glass floor. A rat is placed in the box an d left free to habituate for 10 minutes. Then, a mobile infrared radiant source (setting 20) is focused under the non -lesioned and lesioned hindpaws and the paw -withdrawal latencies are automatically recorded.
- Paw -withdrawal interrupts the reflected radiation and switches off the counter and the light source.
- the test is terminated after 45 seconds.
- the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor.
- the tip of an electronic Von Frey probe is then applied with increasing pressure to the non-lesioned and lesioned hindpaws and the force required to induce paw-withdrawal is automatically recorded. This procedure is carried out 3 times and the mean force per paw is calculated to provide basic scores per animal.
- Prior to receiving drug treatment all animals will be submitted to tactile stimulation and assigned to treatment groups matched on the basis of their pain response.
- mice Male Sprague-Dawley rats (200-250g) are anaesthetised with 2-3% halothane (in 66% N 2 0 and 33% 0 2 ) and subsequently maintained at 1.8% halothane. Core temperature of the animal is monitored using a rectal thermometer probe coupled to a heating blanket. At the end of the experiment, animals are killed with an overdose of anaesthetic. A laminectomy is performed to expose the segments L4 -L5 of the spinal cord, and a paryle ⁇ e -coated tungsten electrode is descended into the dorsal horn using an Epson Stepper device. The depth of the recording site is noted from the microdrive readings.
- Extracellular recordings are made from single dorsal horn neurones receiving C- and A-fibre input from the skin of the hindpaw, identified by their ability to respond to both noxious and innocuous stimuli (pinch and touch).
- Neuronal responses are elicited by transcutaneous electrical stimulation given in the centre of the receptive field of the neurone in the ipsilateral hindpaw, at 3 times the threshold current required for C-fibre evoked activity.
- tests consisting of a train of 16 stimuli (2msec -wide pulses at 0.5Hz) are carried out and post-stimulus histograms constructed.
- evoked response s are separated, according to latency, into A ⁇ -fibre evoked activity (0-20 msec post -stimulus); A ⁇ - fibre evoked activity (20-90 msec); C-fibre evoked activity (90-300 msec) and post- discharge of the neurone (300-800 msec).
- the neuronal response evoked by the first stimulus of the train is referred to as "input” and consists of the number of action potentials (90-800msec) evoked by this stimulus.
- Wind -up a measure of the enhanced neuronal response elicited by repetitive stimulation, is quantified as the difference between the total number of action potentials p roduced by the 16 stimuli (90-800 ms), and the input x 16.
- the measure of wind -up includes both the enhanced C-fibre evoked responses and the post -discharge generated as wind-up ddeevveellooppss.
- VVoonn FFrreeyyy hhaaiirrss ((11 --7755gg)) aanndd hheeaatt ((3300--4488°C) are also used to quantify responses to natural mechanical and thermal stimuli.
- Tests are performed at 10 -minute intervals, until the neuronal responses evoked at each test differed by less than 10%. The results of the last three tests are then averaged to give control values for each parameter.
- Cumulative doses of the compound are then applied to the exposed spinal cord into a 'well' formed by the laminectomy which held the 50 ⁇ l volume of drug.
- the neuronal responses are followed for 60 minutes after each dose, after which the solution can be removed and the next dose applied. Similarily, systemic effects can be measured using subcutaneous injection in 0.2ml.
- Data are shown as percentage of pre -drug control values, with a 60 minute time- course for each dose of the drug. To generate a dose response curve, the maximum effects of each dose on each neurone are averaged. Data are presented as mean + s.e.m. 10 Neurones are needed for each route. A comparison is made with the effects of the compound (by the most effe ctive route as determined by the above studies) in normal animals with that seen 3 hours after carrageenan inflammation. Thus a total of 30 experiments are done - one neurone per animal and each study lasts one day.
- CARRAGEENAN EDAMA TEST A MODEL FOR INFLAMMATORY PAIN
- Carrageenan Edema Test in the rat follows that described by Winter et al. ( Proc.Soc. Exp. Biol. Med.1962, 111: 544-547): solution into the lower surface of the right hind - paw (0.75 mg per paw in 0.05 ml physiological saline). 2 hours later rats are submitted consecutively to thermal and tactile stimulation of both the non -inflamed and the inflamed hindpaws.
- the apparatus Ugo Basile, Reference: 7371 ) consists of 6 individual Plexiglas boxes (17 x 11 x 13 cm) placed upon an elevated glass floor.
- a rat is placed in the box and left free to habituate for 10 minutes.Then, a mobile infrared radiant source (setting 20) is focused under the non-inflamed and inflamed hindpaws and the paw -withdrawal latencies are automatically recorded. Paw-withdrawal interrupts the reflected radiation and switches off the counter and the light source. In order to prevent tissue damage, if no reaction is noted, the test is terminated after 45 seconds. For tactile stimulation, the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor.
- Yeast Hyperthermia Test in the mouse or rat according to by Teotino et al (J. Med.Chem. 1963, 6: 248): Animals are first measured for rectal temperature using a rectal probe. They are then injected with a yeast suspension (512 mg/kg s.c ). 8 hours later, the test substance is administered. Mice are measured for rectal temperature immediately before test substance administration and again 60 and 120 minutes later.
- Results are given as mean ⁇ SD.
- the number of abdominal constrictions at 30, 60, 90 and 120 min after administration of substance or vehicle as well as the mean values (30-120 min) are compared to prevalues (time 0) by paired two sided t -tests. Values of p ⁇ 0.5 are taken as statistically significant.
- NEUROPROTECTIVE ACTIVITY INDUCTION OF GROWTH FACTORS
- RNA is extracted from the individual brain samples and induction of the growth factors BDNF and GDNF is determined by quantitative PCR. Total RNA is isolated with the Trizol method (Invitrogen) from the brain pieces. cDNA is made starting with 2 ⁇ g of total RNA (pretreated for 30 min with DNAse (Ambion) in first strand buffer) using the reverse transcriptase Superscript II (Invitrogen).
- Quantification of mDNA by real time PCR makes use of the observation that the early cycles of PCR are characterized by an exponential increase in target amplification.
- the accumulation of PCR product is measured using Sybergreen II. Primers are designed using the software package Primer Express (Applied Biosystems). Expression levels of the housekeeping genes ornithine decarboxylase (ODC_ex8) and alpha tubulin (TUBA) are used for normalization and as control for good cDNA synthesis.
- ODC_ex8 ornithine decarboxylase
- TUBA alpha tubulin
- Hot plate test In mouse or rat according to Eddy and Leimbach ( J. Pharmacol. Exp.Ther. 1953, 107: 385-393): Mice or rats are placed onto a hot metal plate maintained at 54°C for mice or 52°C. for rats surrounded by a Plexiglas cylinder (Height: 13 cm; Diameter: 19 cm). The latency to the first foot -lick is measured (maximum: 30 seconds).
- Tail flick test in mouse or rat according to by D'Amour and Smith ( J. Pharmacol. Exp.Ther.1941 , 72: 74-79): The animal's tail is heated by means of a thermal light source. The latency before the animal withdraws its tail is measured (maximum: 15 seconds for mice, 30 seconds for rats).
- Phenylbenzoquinone and acetic writhing tests in mice follow the methods described by Hendershot et al (J. Pharmacol. Exp. Ther. 1959, 125: 237-240): Mice are injected with phenylbenzoquinone (PBQ) (1.25 mg/kg i.p.) or acetic acid (0.5% i.p.). This treatment induces a recognizable writhing response in control animals. The number of writhes is counted for 10 minutes beginning 5 minutes after injection of PBQ or acetic acid.
- PBQ phenylbenzoquinone
- Chronic inflammatory pa in test (Freund's adjuvant test) in the rat according to Whiteley (Current Protocols in Pharmacology, Wiley, N.Y., 5.5, 1999 ): an injection of Freund's adjuvant in rats induces chronic clinical signs of polyarthritis with pain.
- rats are weighed and injected i ⁇ tradermally with a suspension of Mycobacterium butyricum (Freund's adjuvant) into the proximal quarter of the tail (1 mg in 0.1 ml mineral oil). Sham controls receive a similar injection of mineral oil.
- rats are weighed again and are evaluated for clinical symptoms of inflammation.
- each paw is scored for inflammation according to a 5-point scale (0-4) and the tail according to a 4-point scale (0-3), i.e. a maximum score of 19 per animal.
- the apparatus Ugo Basile, Reference: 7371
- a mobile infrared radiant source (setting 20) is focused under each hindpaw and the paw - withdrawal latency is automatically recorded. Paw -withdrawal interrupts the reflected radiation and switches off the counter and the light source.
- the test is terminated after 45 seconds.
- the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor.
- the tip of an electronic Von Frey probe (Bioseb, Model 1610) is then applied with increasing pressure to each hindpaw and the force required to induce paw-withdrawal is automatically recorded. This procedure is carried ou t 3 times and the mean force per paw is calculated to provide basic scores per animal.
- Prior to receiving drug treatment all animals will be submitted to tactile stimulation and assigned to treatment groups matched on the basis of their pain response.
- Receptor binding data were obtained by CEREP (128, rue Danton, 92500 Rueil - Malmaison, France) or at Solvay Pharmaceuticals B.V., using well documented standard procedures. Affinity for 5-HT1A receptors for instance, was determined by testing the ability of the compounds of the invention to displace [ 3H]-2-(di-n- propylamino)-8-hydroxytetralin ([3H]-8-OH-DPAT) from its specific binding sites in rat frontal cortex homogenates. This test is based on the method described by Gozlan et al. (Nature, 305. (1983), pages 140-142).
- the affinity of the compounds of the invention for serotonin receptors was determined as described above. From the binding affinity measured for a given compound of formula (1 ), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured K r value, 100% of the receptors are likely to be occupied by the compound. Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mgtkg, preferably 0.1 -100 mgtkg of patient's bodyweight.
- NMR spectra were recorded on a Bruker AM400 spectrometer , or a Varian VXR400S spectrometer. Chemical shifts ( ⁇ ) were reported in ppm downfield from TMS as internal standard.
- a sample of 10-50 mg was dissolved in a deuterated solvent, usually CDCI 3 or a DMSO-d6/CDCI 3 (4:1 v/v) mixture). The solvent was selected to ensure complete dissolution of the sample.
- the fre e induction decays were generally obtained at room temperature under the following conditions:
- Carrier frequency 6.0 ppm Number of acquisitions 128 or more if necessary.
- the C-13 satellite signals at 0.5% signal intensity should be clearly visible.
- Potentiometric chloride determinations were used in this syntheses to determine chloride.
- the titration was performed with a combined silver electrode and silve r nitrate titrant.
- the method is specific for chloride because it can distinguish chloride from iodide and bromine on basis of different electrode potentials.
- the first step was the nitration of 5-bromo-2-hydroxybenzaldehyde (1*) yielding 5- bromo-2-hydroxy-3-nitrobenzaldehyde (2*):
- 5-bromo-2-hydroxybenzaldehyde (1*) was identified by its characteristic chemical shift ⁇ 9.84 ppm; 5-bromo-2-hydroxy-3-nitrobenzaldehyde (2*) had a characteristic chemical shift of ⁇ 10.4 ppm.
- the second step was the Erlenmeyer condensation of 5-bromo-2-hydroxy-3- nitrobenzaldehyde (2*) with N-acetyl-glycine to yield N-(6-bromo-8-nitro-2-oxo-2H-1- benzopyran-3-yl)acetamide (3*).
- the third step was the catalytic hydrogenation of N-(6-bromo-8-nitro-2-oxo-2H-1- benzopyran-3-yl)acetamide (3*) to N-(8-amino-2-oxo-2H-1-benzopyran-3-yl)-acet- amide (4*).
- the filtrate was concentrated to 2 litre, and 2.3 litre of MEK was added In order to change the solvent from ethanol to MEK, 2 litre of the solvent mixture was distilled off at normal pressure and 2 litre of MEK was added. This was repeated 4 times. Then 5 litre of MEK and 2.6 litre of water were added and the mixture was stirred. The layers were separated. The upper later was concentrated at normal pressure to approximately 3.5 litre. The residue was cooled to 25°C. During this cooling the product crystallized. Then the mixture was cooled to -10°C and stirred for two hours. The solid was f iltered and washed three times with 800 ml hexane. The product was dried (50°C, 20 cm Hg, N 2 ) until constant weight.
- N-(6-bromo-8-nitro-2-oxo-2H-1-benzopyran-3-yl)acetamide (3*) had a characteristic chemical shift of ⁇ 8.72 ppm; that of N -(8-amino-2-oxo-2H-1-benzo-pyran-3-yl)- acetamide (4) was ⁇ 8.55 ppm
- T e overall yield of this step was approximately 70% (crude on crude).
- Step 4 was the alkylation of N-(8-amino-2-oxo-2H-1-benzopyran-3-yl)-acetamide (4*) with bis-chloroethylamine yielding N-(8-(1-piperazinyl)-2-oxo-2H-1-be ⁇ zopyran- 3-yl-) acetamide (5*).
- Step 5 was the hydrolysis of the amide function of N-(8-(1 -piperazinyl)-2-oxo-2H-1- benzopyran-3-yl-)acetamide (5*) using hydrochloric acid . This resulted in the trihydrochloric acid salt of 3-amino-8-(1 -piperazinyl)-2H-1-benzopyran-2-one (6*).
- N-(8-(1-piperazinyl)-2-oxo-2H-1-benzopyran-3-yl-)acetamide had a characteristic chemical shift of ⁇ 8.57 ppm; the trihydrochloric acid salt of 3-amino-8-(1- piperazinyl)-2H-1-benzopyran-2-one (6*) had a characterristic chemical shift of ⁇ 6.77 ppm.
- the dried product (1 mol) was dissolved in 9 litre methanol by heating to reflux temperature. The solution did not become completely clear. After cooling to 20 °C the mixture was filtered. 300 ml of water and 150 ml of methanol was added to the filtrate, after which about 3 litre of the solvent mixture was distilled at normal pressure. The complete procedure was repeated with another mol of the dried product. Then the combined fractions wre concentrated to a volume of about 12 litre by distillation. After addition of 6 litre ethanol, 6 litre of the solvent mixture was removed by distillation at normal pressure. The mixture was then cooled to 0°C and stirred for 2 hours. The precip itate was collected on a filter and washed twice with 750 ml acetone. The product was dried under vacuum (40°C, 200 mm Hg, N 2 , 24 hours), and thereafter homogenized by milling and, when necessary, by micronizing.
- COMPOUND 1 the mono hydrochloric acid mono hydrate of 3-amino-8-(1 - piperazinyl)-2H-1-be ⁇ zopyran-2-o ⁇ e, had a molecular formula C 13 H ⁇ 8 CIN 3 0 3 and a molecular mass of 299.5.
- the pure product 99.8%, NMR was a white to yellowish powder. Its chloride content was 11.7% (mass to mass), as determined by titrimetry. Its water content, determined by Karl Fisher water assay titration, was 6.5% (mass to mass).
- i p intraperitoneal (i p) administration: to the desired quantity (0.5-15 mg) of the solid compound 1 in a glass tube, some glass beads were added and the solid was milled by vortexing for 2 minutes. After addition of 1 ml of a solution of 1% methylcellulose and 5% mannitol in water, the compound was suspended by vortexing for 10 minutes. Finally the pH was adjusted to 7.
- Compound 1 exhibited a significant inhibition of the number of abdominal contractions due to colorectal distention after sensitization with acetic acid in the dose range between 3 and 10 ⁇ mol/kg 90 minutes after subcutaneous administration.
- the vehicle used for this dose did not interfere with the experimental protocol.
- Treatment with Compound 1 increased GDNF and BDNF RNA levels in the thalamus, striatum, prefrontal cortex, nucleus accumbens and hippocampus (see table)
- Compound 1 is also orally active in this test in mice: its' ED 50 is 3.2 mg/kg (p.o.)
- Compound 1 is active in this test: its' ED 50 is 1.82 mg/kg p.o.
- binding data collected in the table below were either obtained by CEREP (128, rue Danton, 92500 Rueil-Malmaison, France) or at Solvay Pharmaceuticals B.V., using well documented standard procedures.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT05729786T ATE482707T1 (en) | 2004-03-25 | 2005-03-23 | 1-Ä2H-1-BENZOPYRAN-2-ON-8-YLÜ-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN |
PL05729786T PL1732558T3 (en) | 2004-03-25 | 2005-03-23 | 1-[2h-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of pain |
EP05729786A EP1732558B1 (en) | 2004-03-25 | 2005-03-23 | 1-[2h-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of pain |
DE602005023842T DE602005023842D1 (en) | 2004-03-25 | 2005-03-23 | 1-Ä2H-1-BENZOPYRAN-2-ON-8-YLÜPIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN |
CA002554074A CA2554074A1 (en) | 2004-03-25 | 2005-03-23 | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain |
JP2007504418A JP2007530509A (en) | 2004-03-25 | 2005-03-23 | 1- [2H-1-benzopyran-2-one-8-yl] -piperazine derivatives for the treatment of pain |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55596604P | 2004-03-25 | 2004-03-25 | |
US60/555,966 | 2004-03-25 | ||
EP04101230 | 2004-03-25 | ||
EP04101230.3 | 2004-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092340A1 true WO2005092340A1 (en) | 2005-10-06 |
Family
ID=34928928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/051328 WO2005092340A1 (en) | 2004-03-25 | 2005-03-23 | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050215567A1 (en) |
EP (1) | EP1732558B1 (en) |
JP (1) | JP2007530509A (en) |
AR (1) | AR048112A1 (en) |
AT (1) | ATE482707T1 (en) |
CA (1) | CA2554074A1 (en) |
PL (1) | PL1732558T3 (en) |
PT (1) | PT1732558E (en) |
TW (1) | TWI350753B (en) |
WO (1) | WO2005092340A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7822488B2 (en) * | 2004-03-23 | 2010-10-26 | Koninklijke Philips Electronics N.V. | Self-storing medical electrodes |
WO2018069278A1 (en) * | 2016-10-10 | 2018-04-19 | Basf Se | Catalyst modification with alkali metal ions, alkaline earth metal ions or rare earth metal ions in the continuous liquid-phase hydrogenation of nitro compounds |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR049478A1 (en) * | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS. |
US20060013874A1 (en) * | 2004-07-15 | 2006-01-19 | Solvay Pharmaceuticals B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one |
MX2011013324A (en) * | 2009-06-10 | 2012-04-30 | Abbott Gmbh & Co Kg | Use of substituted oxindole derivatives for the treatment and prophylaxis of pain. |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0189612A1 (en) * | 1984-12-21 | 1986-08-06 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
EP0372657A1 (en) * | 1988-12-08 | 1990-06-13 | Duphar International Research B.V | Anxiolytically active piperazine derivatives |
EP0490772A1 (en) * | 1990-12-14 | 1992-06-17 | Adir Et Compagnie | 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them |
EP0650964A1 (en) * | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives |
WO1997036893A1 (en) * | 1996-03-29 | 1997-10-09 | Duphar International Research B.V. | Piperazine and piperidine compounds |
WO1999039128A1 (en) | 1998-01-28 | 1999-08-05 | Dolmar Gmbh | Chain fluid pump for a power chain saw and power chain saw comprising such a chain fluid pump |
WO1999052907A1 (en) | 1998-04-09 | 1999-10-21 | Pfizer Products Inc. | Azabicyclic 5ht1 receptor ligands |
WO2000039128A1 (en) * | 1998-12-28 | 2000-07-06 | Pfizer Products Inc. | 5ht1 antagonists for antidepressant therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
FR2667068B1 (en) * | 1990-09-26 | 1994-09-09 | Adir | NOVEL HETEROCYCLIC ALKYL AMINES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
NL9401572A (en) * | 1994-09-27 | 1996-05-01 | Avebe Coop Verkoop Prod | Starch products such as tableting excipient, method of preparation thereof, and method of making tablets. |
US6342498B1 (en) * | 1997-10-22 | 2002-01-29 | Eli Lilly And Company | Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists |
US6376494B1 (en) * | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6312717B1 (en) * | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
GB0008563D0 (en) * | 2000-04-07 | 2000-05-24 | Cambridge Discovery Chemistry | Investigating different physical and/or chemical forms of materials |
US20030008880A1 (en) * | 2001-05-02 | 2003-01-09 | Pfizer Inc. | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
AR039164A1 (en) * | 2002-03-28 | 2005-02-09 | Synthon Bv | VENLAFAXINE SALTS OF LOW WATER SOLUBILITY |
US20050215551A1 (en) * | 2004-03-25 | 2005-09-29 | Solvay Pharmaceuticals B.V. | 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders |
AR049478A1 (en) * | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS. |
-
2005
- 2005-03-21 AR ARP050101093A patent/AR048112A1/en unknown
- 2005-03-22 TW TW094108780A patent/TWI350753B/en not_active IP Right Cessation
- 2005-03-22 US US11/085,193 patent/US20050215567A1/en not_active Abandoned
- 2005-03-23 PT PT05729786T patent/PT1732558E/en unknown
- 2005-03-23 WO PCT/EP2005/051328 patent/WO2005092340A1/en not_active Application Discontinuation
- 2005-03-23 AT AT05729786T patent/ATE482707T1/en active
- 2005-03-23 JP JP2007504418A patent/JP2007530509A/en not_active Ceased
- 2005-03-23 EP EP05729786A patent/EP1732558B1/en not_active Not-in-force
- 2005-03-23 CA CA002554074A patent/CA2554074A1/en not_active Abandoned
- 2005-03-23 PL PL05729786T patent/PL1732558T3/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0189612A1 (en) * | 1984-12-21 | 1986-08-06 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
EP0372657A1 (en) * | 1988-12-08 | 1990-06-13 | Duphar International Research B.V | Anxiolytically active piperazine derivatives |
EP0490772A1 (en) * | 1990-12-14 | 1992-06-17 | Adir Et Compagnie | 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them |
EP0650964A1 (en) * | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives |
WO1997036893A1 (en) * | 1996-03-29 | 1997-10-09 | Duphar International Research B.V. | Piperazine and piperidine compounds |
WO1999039128A1 (en) | 1998-01-28 | 1999-08-05 | Dolmar Gmbh | Chain fluid pump for a power chain saw and power chain saw comprising such a chain fluid pump |
WO1999052907A1 (en) | 1998-04-09 | 1999-10-21 | Pfizer Products Inc. | Azabicyclic 5ht1 receptor ligands |
WO2000039128A1 (en) * | 1998-12-28 | 2000-07-06 | Pfizer Products Inc. | 5ht1 antagonists for antidepressant therapy |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7822488B2 (en) * | 2004-03-23 | 2010-10-26 | Koninklijke Philips Electronics N.V. | Self-storing medical electrodes |
WO2018069278A1 (en) * | 2016-10-10 | 2018-04-19 | Basf Se | Catalyst modification with alkali metal ions, alkaline earth metal ions or rare earth metal ions in the continuous liquid-phase hydrogenation of nitro compounds |
US10538478B2 (en) | 2016-10-10 | 2020-01-21 | Basf Se | Catalyst modification with alkali metal, alkaline earth metal or rare earth metal ions in the continuous liquid-phase hydrogenation of nitro compounds |
Also Published As
Publication number | Publication date |
---|---|
PL1732558T3 (en) | 2011-03-31 |
CA2554074A1 (en) | 2005-10-06 |
ATE482707T1 (en) | 2010-10-15 |
PT1732558E (en) | 2010-12-23 |
EP1732558B1 (en) | 2010-09-29 |
TW200534847A (en) | 2005-11-01 |
EP1732558A1 (en) | 2006-12-20 |
US20050215567A1 (en) | 2005-09-29 |
JP2007530509A (en) | 2007-11-01 |
AR048112A1 (en) | 2006-03-29 |
TWI350753B (en) | 2011-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023513679A (en) | Silosine derivatives as serotonergic hallucinogens for the treatment of central nervous system disorders | |
CN105744932B (en) | For treating the composition comprising Torasemide and Baclofen of neurological disorder | |
JP2010511616A (en) | Means for improving cognitive function and memory based on hydrogenated pyrido (4,3-b) indoles (isomers), pharmacological means based on the means, and methods for use of the means | |
EP1732558B1 (en) | 1-[2h-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of pain | |
JP2006514056A (en) | Method of treating pain and traumatic injury using benzamide compounds and compositions containing benzamide compounds | |
SG178000A1 (en) | Methods and combination therapies for treating alzheimer's disease | |
EP3570940B1 (en) | Pridopidine for use in the treatment of fragile x syndrome | |
CA2711957A1 (en) | Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments | |
SK283497B6 (en) | The use of N-methyl-N-[(1S)-1-phenyl-2-((3S)- 3-hydroxypyrrolidine-1-yl)ethyl]-2, 2-diphenylacetamidehydrochloride for production of pharmaceutical composition | |
MX2015004162A (en) | Novel uses. | |
JP2012529477A (en) | Neuroprotective properties of 5'-methylthioadenosine | |
WO2013112363A1 (en) | Method of treating tourette's disorder with gaba-aminotransferase inactivators | |
EP2024364A1 (en) | Heterocyclic compounds as calcium channel blockers | |
SA05260060B1 (en) | 1-[2h-1-benzopyran-2-one8-y1]-piperazine derivatives for the treatment of pain | |
CN114504579A (en) | Compound for preventing and treating pain and inflammation and application thereof | |
JP2015534990A (en) | Compositions and methods for treating or preventing diseases or disorders associated with miscontrolled eIF4E | |
EP0596326B1 (en) | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | |
ES2353702T3 (en) | DERIVATIVES OF 1- [2H-1-BENZOPIRAN-2-ONA-8-IL] -PIPERAZINE FOR THE TREATMENT OF PAIN. | |
CA2429216C (en) | Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors | |
Azadbakht et al. | Doxepin improves stress-impaired long-term potentiation and gene expression of BDNF in the rat hippocampus | |
WO2023126076A1 (en) | Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome | |
Mody et al. | In search of novel and therapeutically significant melatoninergic ligands | |
EP1623709A1 (en) | Remedy for rheumatoid arthritis | |
EP0460358B1 (en) | Agent for treating disorders from cerebral neuro-degeneration | |
ÖZKAN et al. | Health Sciences Studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005729786 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554074 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007504418 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005729786 Country of ref document: EP |